Synergistic effects of imatinib and carboplatin on VEGF, PDGF and PDGF-Rα/β expression in squamous cell carcinoma of the head and neck in vitro

International Journal of Oncology

Volumn 38, Issue 4, 2011, Pages 1001-1012

  Schultz, J D ^a   Rotunno, S ^a   Riedel, F ^a   Anders, C ^a   Erben, P ^a   Hofheinz, R D ^a   Faber, A ^a   Thorn, C ^a   Sommer, J U ^a   Hormann K ^a   Sauter, A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Carboplatin; Head and neck squamous cell carcinoma; Imatinib; PDGF R ; Platelet derived growth factor; Protein tyrosin kinase; Vascular endothelial growth factor

Indexed keywords

ABELSON KINASE; CARBOPLATIN; IMATINIB; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME REPRESSION; GENE REPRESSION; HEAD AND NECK CARCINOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REAL TIME QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA; TRANSCRIPTION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952329925     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.912     Document Type: Article

References (57)

1. Parkin DM, Bray F, Ferlay J, et al: Global Cancer Statistics. J Clin Cancer 55: 74-108, 2002.
2. IARC (International Agency for Research on Cancer): Globocan. www.dep.iarc.fr, 2002.
3. Ries LAG, Eisner MP, Kosary CL, et al: SEER Cancer Statistics Review: 1975-2002. National Cancer Institute, Bethesda, 2005.
4. De Wever O and Mareel M: Role of tissue stroma in cancer cell invasion. J Pathol 200: 429-447, 2003. (Pubitemid 36818244)
5. Tlsty TD and Hein PW: Know their neighbor: stromal cells can contribute oncogenic signals. Curr Opin Genet Dev 11: 54-59, 2001. (Pubitemid 32119278)
6. Bhowmick NA, Neilson EG, Moses HL, et al: Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337, 2004. (Pubitemid 39551661)
7. Bhowmick NA, Chytil A, Plieth D, et al: TGFbeta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303: 848-851, 2004. (Pubitemid 38174665)
8. Micke P and Ostman A: Exploring the tumour environment: cancerassociated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 9: 1217-1233, 2005. (Pubitemid 41762875)
9. Joyce JA: Therapeutic targeting of the tumor microenvironment. Cancer Cell 7: 513-520, 2005.
10. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000. (Pubitemid 30046295)
11. Park CC, Bissell MJ, Barcellos-Hoff MH, et al: The influence of the microenvironment on the malignant phenotype. Mol Med Today 6: 324-329, 2000. (Pubitemid 30619340)
12. Pietras K, Sjoblom T, Rubin K, et al: PDGF receptors as cancer drug targets. Cancer Cell 3: 439-443, 2003. (Pubitemid 38340290)
13. Board R and Jayson GC: Platelet-derived growth factor receptor (PDGFR): a target for anticancer therapeutics. Drug Resist Updat 8: 75-83, 2005. (Pubitemid 40797958)
14. Heldin CH and Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316, 1999.
15. Betsholtz C, Karlsson L, Lindahl P, et al: Developmental roles of platelet-derived growth factors. Bioessays 23: 494-507, 2001. (Pubitemid 32575610)
16. Yu J, Ustach C and Kim HR: Platelet-derived growth factor signaling and human cancer. J Biochem Mol Biol 36: 49-59, 2003. (Pubitemid 36836256)
17. Thommen R, Humar R, Misevic G, et al: PDGF-BB increases endothelial migration on cord movements during angiogenesis in vitro. J Cell Biochen 64: 403-413, 1997. (Pubitemid 27098626)
18. Tejada ML, Yu L, Dong J, et al: Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. Clin Cancer Res 12: 2676-2688, 2006.
19. Risau W, Drexler H, Mironov V, et al: Platelet-derived growth factor is angiogenic in vivo. Growth Factors 7: 261-266, 1992. (Pubitemid 23079516)
20. Pietras K, Ostman A, Sjöquist M, et al: Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors. Cancer Res 61: 2929-2934, 2001. (Pubitemid 32691937)
21. Forsberg K, Valyi-Nagy I and Heldin C-H: Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci USA 90: 393-397, 1993. (Pubitemid 23028868)
22. Dong J, Grunstein J, Tejada M, et al: VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 23: 2800-2810, 2004. (Pubitemid 39013552)
23. Shao Z-M, Nguyen M, Barsky SH, et al: Human breast carcinoma desmoplasia is PDGF initiated. Oncogene 19: 4337-4345, 2000.
24. Skobe M and Fusenig NE: Tumorigenic conversion of immortal human keratinocytes through stromal cell activation. Proc Natl Acad Sci USA 95: 1050-1055, 1998. (Pubitemid 28124910)
25. Dvorak HF, Brown LF, Detmar M, et al: Vascular permeability factor/vascular endothelial growth factor, microvascular hyper-permeability and angiogenesis. Am J Pathol 146: 1029-1039, 1995.
26. Ferrara N: The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36: 127-137, 1995.
27. Zhang HT, Craft P, Scott PA, et al: Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. Natl Cancer Inst 87: 213-219, 1995.
28. Eisma RJ, Spiro JD, Kreutzer DL, et al: Vascular endothelial growth factor expression in head and neck squamous cell carcinoma. Am J Surg 174: 513-517, 1997. (Pubitemid 27486016)
29. Mineta H, Miura K and Ogino T: Prognostic value of vascular endothelial growth factor in head and neck squamous cell carcinomas. Br J Cancer 83: 775-781, 2000.
30. Salven P, Heikkilä P and Anttonen A: Vascular endothelial growth factor in squamous cell head and neck carcinoma: expression and prognostic significance. Mod Pathol 10: 1128-1133, 1997. (Pubitemid 27521291)
31. Riedel F, Götte K and Schwalb J: Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol 257: 332-336, 2000. (Pubitemid 30612326)
32. Riedel F, Götte K and Schwalb J: Expression of vascular endothelial growth factor correlates with angiogenesis and p53 mutations in head and neck squamous cell carcinoma. Acta Otolaryngol 120: 105-111, 2000. (Pubitemid 30434141)
33. Riedel F, Götte K, Bergler W, et al: Inverse correlation of angiogenic and apoptotic markers in squamous cell carcinoma of the head and neck. Oncol Rep 8: 471-476, 2001. (Pubitemid 33758439)
34. Blume-Jensen P and Hunter T: Oncogenic kinase signalling. Nature: 411: 355-365, 2001. (Pubitemid 32467045)
35. Druker BJ and Lydon NB: Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3-7, 2000. (Pubitemid 30036380)
36. O'Dwyer ME, Mauro MJ, Druker BJ, et al: STI571 as a targeted therapy for CML. Cancer Invest 21: 429-438, 2003. (Pubitemid 37055675)
37. Roskoski R Jr: STI-571: an anticancer protein-tyrosine kinase inhibitor. Biochem Biophys Res Commun 309: 709-717, 2003.
38. Shore SK, Bogart SL, Reddy EP, et al: Activation of murine c-Abl protooncogene: effect of a point mutation on oncogenic activation. Proc Natl Acad Sci USA 87: 6502-6506, 1990.
39. Croom KF and Perry CM: Imatinib mesylate: in the treatment of gastrointestinal stromal tumours. Drugs 63: 513-522, 2003. (Pubitemid 36337730)
40. Demetri GD, von Mehren M, Blanke CD, et al: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002. (Pubitemid 34879334)
41. Wang-Rodriguez J, Lopez JP and Altuna X: STI-571 (Gleevec) potentiates the effect of cisplatin in inhibiting the proliferation of head and neck squamous cell carcinoma in vitro. Laryngoscope 116: 1409-1416, 2006. (Pubitemid 44181456)
42. Kano Y, Akutsu M, Tsunoda S, et al: In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood 97: 1999-2007, 2001.
43. Faivre S, Raymond E, Casiraghi O, et al: Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J Clin Oncol 23: 6271-6273, 2001.
44. Zhang P, Gao WY, Turner S and Ducatman B: Gleevec (STI 571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer 2: 1-9, 2003.
45. Bruce IA, Slevin NJ, Homer JJ, McGown AT and Ward TH: Synergistic effects of imatinib (STI 571) in combination with chemotherapeutic drugs in head and neck cancer. Anticancer Drugs 16: 719-726, 2005. (Pubitemid 41104920)
46. Bellone G, Ferrero D, Carbone A, et al: Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI 571. Cancer Biol Ther 3: 385-392, 2004. (Pubitemid 41350868)
47. Pietras K, Rubin K, Sjoblom T, et al: Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy. Cancer Res 62: 5476-5484, 2002.
48. Fan S, el-Deiry WS, Bae I, et al: p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54: 5824-5830, 1994.
49. Gong B and Almasan A: Differential upregulation of p53-responsive genes by genotoxic stress in hematopoietic cells containing wild-type and mutant p53. Gene Expr 8: 197-206, 1999. (Pubitemid 30235331)
50. Erben P, Gosenca D, Müller MC, et al: Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Haematologica 95: 738-744, 2010.
51. Muller MC, Erben P, Saglio G, et al: Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 22: 96-102, 2008.
52. Bran B, Bran G, Hörmann K, et al: The platelet-derived growth factor receptor as a target for vascular endothelial growth factor-mediated anti-angiogenetic therapy in head and neck cancer. Int J Oncol 34: 255-261, 2009.
53. Kitamura Yand Hirotab S: Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci 61: 2924-2931, 2004.
54. Bishayee S, Ross AH, Womer R, et al: Purified human platelet-derived growth factor receptor has ligand-stimulated tyrosine kinase activity. Proc Natl Acad Sci USA 83: 6756-6760, 1986. (Pubitemid 16002312)
55. Beppu K, Jaboine J, Merchant MS, et al: Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 96: 46-55, 2004. (Pubitemid 38180959)
56. Matei D, Kelich S, Cao L, et al: PDGF BB induces VEGF secretion in ovarian cancer. Cancer Biol Ther 6: 1951-1959, 2007.
57. Vlahovic G, Ponce AM, Rabbani Z, et al: Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. Br J Cancer 97: 735-740, 2007. (Pubitemid 47396288)